

## P02 International Survey on Oral Anticancer Drugs

J. Rosentreter, M. Kuzmanovic, A. Amidi, A. Balogh, A. Bello, Z. Bodor, L. Budau, C. Carbasse, D. Eppel, F. Festinese, S. Kamal, N. Kizilmese, K. Meier, S. Mira, I. Netikova, M. Saar, C. Schramm, K. Vermis

ESOP Global Special Interest Group (SIG) Oral Cancer Drugs

### Introduction

The use of oral anticancer drugs has increased during the last decade, because of patient preference, lower costs, proven efficacy, lack of infusion related inconveniences, and the opportunity to develop chronic treatment regimens. Although most drugs are EMA and thus European wide approved, access, availability and dispensing situations differ greatly between countries.

### Material and methods

The ESOP Global Special Interest Group (SIG) has created a survey to assess various topics about dispensing oral anticancer drugs, the healthcare system and patient counseling. The 25 questions were translated from English to 13 other languages to reach a broad international audience.

The link for the online survey (valid for four weeks) was sent to all ESOP Global members (approx. 4.200 individuals in 62 countries) in November 2023.

The questions cover the following topics:

- General (ESOP Global membership, workplace, country of)
- Pharmacists' role in the prescription process
- Reimbursement of oral anticancer drugs
- Patient copayment
- Dispensing details (by whom, to which patient groups, frequency)
- Patient counseling
- Electronic prescription/medical record, information transfer between health professionals

### Results and discussion

Two weeks after initiation, 150 responses have been received. The complete evaluation will take place from January 2024 on. The results will be shared via the ESOP Global newsletter and presented at the ECOP 6 (Lisbon, 2024). The results will help to identify important topics and/or barriers concerning oral anticancer drugs, patient counseling and thereby guide the SIG's further work.

### Conclusion

Oral anticancer drugs have proved essential for the treatment of many types of cancer. Within the last decade, the specialty of oncology pharmacy developed and gained knowledge and experience to serve the expanding demands of the health system regarding oral anticancer drugs. Pharmacists are essential to both expanding and enhancing the care of patients with cancer and should be leveraged to improve patients' outcome whenever possible.

### Keywords

oral anticancer drugs, pharmacist, pharmaceutical care, patient counseling, supportive care